The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials
Abstract
Background and Purpose—: TNK (tenecteplase), a newer fibrinolytic agent, has practical delivery advantages over ALT (alteplase) that would make it a useful agent if noninferior in acute ischemic stroke treatment outcome. Accordingly, the most recent US American Heart Association/American Stroke Association acute ischemic stroke guideline recognized TNK as an alternative to ALT, but only based on informal consideration, rather than formal meta-analysis, of completed randomized control trials. Methods—: Systematic literature search and formal meta-analysis were conducted per PRISMA guidelines (Preferred Reporting Items for Systemic Reviews and Meta-Analyses), adapted to noninferiority analysis. The primary outcome of freedom from disability (modified Rankin Scale score, 0–1) outcome at 3 m, and additional efficacy and safety outcomes, were analyzed. Results—: Systematic search identified 5 trials enrolling 1585 patients (828 TNK, 757 ALT). Across all trials, mean age was 70.8, 58.5% male, baseline National Institutes of Health Stroke Scale mean 7.0, and time from last known well to treatment start mean 148 minutes. All ALT patients received standard 0.9 mg/kg dosing, while TNK dosing was 0.1 mg/kg in 6.8%, 0.25 mg/kg in 24.6%, and 0.4 mg/kg in 68.6%. For the primary end point, crude cumulative rates of disability-free (modified Rankin Scale score, 0–1) 3 m outcome were TNK 57.9% versus ALT 55.4%. Informal, random-effects meta-analysis, the risk difference was 4% (95% CI, −1% to 8%). The lower 95% CI bound fell well within the prespecified noninferiority margin. Similar results were seen for the additional efficacy end points: functional independence (modified Rankin Scale score, 0–2): crude TNK 71.9% versus ALT 70.5%, risk difference 2% (95% CI, −3% to 6%); and modified Rankin Scale shift analysis, common odds ratio 1.21 (95% CI, 0.93–1.57). For safety end points, lower event rates reduced power, but point estimates were also consistent with noninferiority Conclusions—: Accumulated clinical trial data provides strong evidence that TNK is noninferior to ALT in the treatment of acute ischemic stroke. These findings provide formal support for the recent guideline recommendation to consider TNK an alternative to ALT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emberson, J., Lees, K. R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60584-5 · Cited by 2,737
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Cited by
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Campbell, B. C. V., & Khatri, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31179-x · Cited by 1,116
Management of Acute Ischemic Stroke
Herpich, F., & Rincon, F. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004597 · Cited by 933
Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review
Mendelson, S. J., & Prabhakaran, S. (2021) · JAMA · doi:10.1001/jama.2020.26867 · Cited by 784
Hilkens, N. A., Casolla, B., Leung, T. W., & de Leeuw, F.-E. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00642-1 · Cited by 681
Management of acute ischemic stroke
Phipps, M. S., & Cronin, C. A. (2020) · BMJ · doi:10.1136/bmj.l6983 · Cited by 611
Menon, B. K., Buck, B. H., Singh, N., Deschaintre, Y., Almekhlafi, M. A., Coutts, S. B., Thirunavukkarasu, S., Khosravani, H., Appireddy, R., Moreau, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01054-6 · Cited by 474
Thrombolysis for acute ischaemic stroke: current status and future perspectives
Tsivgoulis, G., Katsanos, A. H., Sandset, E. C., Turc, G., Nguyen, T. N., Bivard, A., Fischer, U., & Khatri, P. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00519-1 · Cited by 372
Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02600-9 · Cited by 316
Metadata
- Authors
- Burgos, A. M., & Saver, J. L.
- Venue
- Stroke
- Published
- 2019-08
- Volume
- 50
- Issue
- 8
- Pages
- 2156-2162
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2965350298
- Cited by
- 214
- References
- 2
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.